ScandiBio Therapeutics

info@scandibio.com
  • About Us
    • Our Science
    • Scientific rationale
    • The Team
  • Clinical Studies
    • Phase I/II: SERINE
    • Phase I: METABOLIC COFACTORS
    • Phase II: NAFLD
    • Phase II: AD/PD
    • Phase II: COVID-19
    • Phase III: COVID-19
  • Publications
  • News
  • Contact

Yearly Archives: 2021

ScandiBio Therapeutics   →  2021
25
Oct
Date October 25, 2021
Categories News

Metabolic Activators Therapy Improve Liver Fat in NAFLD Patients

A phase-2 human clinical study showed that patients with nonalcoholic fatty liver disease (NAFLD) experienced a significant reduct...
Read More
Author SCANDIBIO
05
Aug
Date August 5, 2021
Categories News

Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Parkinson’s disease patients

ScandiBio Therapeutics announced Phase 2 clinical trial results from the study “Combined Metabolic Activators Improve Cognitive...
Read More
Author SCANDIBIO
20
Jul
Date July 20, 2021
Categories News

Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Alzheimer’s disease patients

ScandiBio Therapeutics announced Phase 2 clinical trial results from the study “Combined Metabolic Activators Improves Cognitive...
Read More
Author SCANDIBIO
29
Jun
Date June 29, 2021
Categories News

The results of a phase II and III clinical trials about the treatment of COVID-19 patients with CMAs have been published at Advanced Science

The results of a Phase II and III studies have been published in the journal Advanced Science. COVID-19 is associated with mi...
Read More
Author SCANDIBIO
24
Feb
Date February 24, 2021
Categories News

Phase 3 human clinical trial shows that metabolic activators accelerates recovery in COVID-19 patients

The Swedish biotechnology company ScandiBio Therapeutics today announced results from the study “Combined Metabolic Activators A...
Read More
Author SCANDIBIO
04
Feb
Date February 4, 2021
Categories News

Phase 2 human clinical trial shows that metabolic activators reduces liver fat in NAFLD patients

ScandiBio Therapeutics announced results from the study “Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty L...
Read More
Author SCANDIBIO

Categories

  • News 16

Recent Posts

  • Metabolic Activators Therapy Improve Liver Fat in NAFLD PatientsOctober 25, 2021
  • Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Parkinson’s disease patientsAugust 5, 2021
  • Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Alzheimer’s disease patientsJuly 20, 2021
  • The results of a phase II and III clinical trials about the treatment of COVID-19 patients with CMAs have been published at Advanced ScienceJune 29, 2021
  • Phase 3 human clinical trial shows that metabolic activators accelerates recovery in COVID-19 patientsFebruary 24, 2021

Archives

  • October 2021
  • August 2021
  • July 2021
  • June 2021
  • February 2021
  • October 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
Copyright © 2020 ScandiBio Therapeutics. All rights reserved.